Key result
Low-dose apixaban yields 0 thromboembolic or bleeding events over 2.5 years in dialysis with mechanical valve.
Why the study?
Vitamin K antagonists are standard anticoagulation for mechanical heart valves but may promote calciphylaxis, whereas direct oral anticoagulants are contraindicated in mechanical heart valves and not recommended in dialysis.
Does low-dose apixaban prevent thromboembolic events and bleeding in an elderly dialysis patient with a mechanical aortic valve and VKA-associated calciphylaxis?
Case Report (n=1)
Does low-dose apixaban prevent thromboembolic events and bleeding in an elderly dialysis patient with a mechanical aortic valve and VKA-associated calciphylaxis?
Low-dose apixaban with plasma level monitoring may serve as a pragmatic alternative anticoagulation strategy in selected patients with long-standing mechanical aortic valves when guideline-recommended VKA therapy is contraindicated due to calciphylaxis.
Answers are grounded in this paper and cite their sources.
Apixaban may be feasible when VKAs fail in this rare setting; hypothesis-generating and challenges consensus pending prospective trials.
BACKGROUND: Vitamin K antagonists (VKAs) remain the standard anticoagulation for mechanical heart valves but may promote vascular calcification and calciphylaxis. CASE SUMMARY: An 88-year-old woman with a longstanding mechanical aortic valve and advanced chronic kidney disease developed biopsy-confirmed calciphylaxis during VKA therapy. Following initiation of hemodialysis, anticoagulation was switched to low-dose apixaban (2.5 mg twice a day) with plasma level monitoring. Over 2.5 years of follow-up, no bleeding, thromboembolic events, or valve-related complications occurred, and renal recovery allowed dialysis withdrawal. WHY BEYOND THE GUIDELINES?: Direct oral anticoagulants are contraindicated in patients with mechanical heart valves and not recommended in dialysis. Apixaban was introduced because of VKA-associated calciphylaxis and limited therapeutic alternatives. DISCUSSION: Apixaban may be used safely in patients with long-standing mechanical aortic valves because of its predictable pharmacokinetics. TAKE-HOME MESSAGE: Apixaban may represent a pragmatic option in selected patients with long-standing mechanical aortic valves when guideline-recommended VKA therapy cannot be maintained.
No takes yet. Share an insight, caveat, or question.
Hueso et al. (2026) conducted a case report in Mechanical aortic valve, advanced chronic kidney disease on hemodialysis, and VKA-associated calciphylaxis (n=1). Apixaban was evaluated on Bleeding, thromboembolic events, or valve-related complications. Low-dose apixaban (2.5 mg twice daily) resulted in 0 bleeding, thromboembolic, or valve-related events over 2.5 years in an 88-year-old dialysis patient with a mechanical aortic valve.
Synapse has enriched 10 related papers. Consider them for comparative context: